Navigation Links
Poniard Pharmaceuticals Initiates Randomized Phase 2 Trial of Picoplatin for First-Line Treatment of Metastatic Colorectal Cancer
Date:11/1/2007

tform product candidate, is a new generation platinum therapy with an improved safety profile. Picoplatin is designed to overcome and prevent platinum resistance associated with chemotherapy in solid tumors, and is being studied in multiple cancer indications, combinations and formulations. Clinical trials of intravenous picoplatin include a Phase 3 trial in small cell lung cancer and Phase 2 trials in metastatic colorectal and hormone- refractory prostate cancer, as well as a Phase 1 clinical trial of oral picoplatin in solid tumors. For additional information please visit http://www.poniard.com.

This release contains forward-looking statements, including statements regarding the Company's business objectives and strategic goals, drug development plans, and the efficacy of its products in development. The Company's actual results may differ materially from those indicated in these forward-looking statements based on a number of factors, including risks and uncertainties associated with the Company's research and development activities; the results of pre-clinical and clinical testing; the receipt and timing of required regulatory approvals; the market's acceptance of the Company's proposed products; the Company's anticipated operating losses, need for future capital and ability to obtain future funding; competition from third parties; the Company's ability to preserve and protect intellectual property rights; the Company's dependence on third-party manufacturers and suppliers; the Company's lack of sales and marketing experience; the Company's ability to attract and retain key personnel; changes in technology, government regulation and general market conditions; and the risks and uncertainties described in the Company's current and periodic reports filed with the Securities and Exchange Commission, including the Company's Annual Report on Form 10-K for the year ended December 31, 2006, as amended, and most cu
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Poniard Pharmaceuticals Announces Promising Data From Interim Safety Analysis of Phase 1 Combination Trials of Picoplatin in Colorectal and Prostate Cancers
2. Poniard Pharmaceuticals Announces Clinical Data from Picoplatin Phase 2 Small Cell Lung Cancer Trial To Be Presented at American Society of Clinical Oncology Annual Meeting
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
9. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
11. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... , March 30, 2015 ... My Diabetes Emergency Plan at the 2015 @NatHurricaneCon ... to be prepared to manage your #diabetes before emergencies ... (ACE) – the charitable, educational and scientific arm of ... joined forces with Lilly Diabetes to share the ...
(Date:3/30/2015)... Calif. , March 30, 2015  The investigational ... agent to alleviate certain menopause symptoms, such as hot ... March Journal of Women,s Health .[i] ... S- equol for menopausal vasomotor symptoms and possibly ... supporting safety of S- equol, physicians and health ...
(Date:3/30/2015)... March 30, 2015  A promising University of Michigan ... with a rare and lethal subtype of leukemia has ... with a new biotechnology company, Kura Oncology.  The Leukemia ... led by Assistant Professor Jolanta Grembecka , Ph.D, ... the University of Michigan, since 2009. ...
Breaking Medicine Technology:Preparation Is Personal for Those with Chronic Illnesses 2Preparation Is Personal for Those with Chronic Illnesses 3Preparation Is Personal for Those with Chronic Illnesses 4New Scientific Review Suggests Some Women May Benefit from Considering Use of S-equol to Ease Menopause Symptoms 2New Scientific Review Suggests Some Women May Benefit from Considering Use of S-equol to Ease Menopause Symptoms 3New Scientific Review Suggests Some Women May Benefit from Considering Use of S-equol to Ease Menopause Symptoms 4New Scientific Review Suggests Some Women May Benefit from Considering Use of S-equol to Ease Menopause Symptoms 5New Scientific Review Suggests Some Women May Benefit from Considering Use of S-equol to Ease Menopause Symptoms 6Leukemia Research Funded by The Leukemia & Lymphoma Society Gets Infusion of Support from Startup Biotechnology Company 2Leukemia Research Funded by The Leukemia & Lymphoma Society Gets Infusion of Support from Startup Biotechnology Company 3
... A unique treatment involving the use of hot chemotherapy ... Center. SJH&MC is the first hospital in Southeast Michigan ... offer the treatment. Know as Hyperthermic Intraperitoneal ... number of advanced cancers that have spread to the ...
... and SYDNEY, Nov. 4, 2011 HeartWare International, Inc. ... leading innovator of less invasive, miniaturized circulatory support technologies ... today announced that CEO Doug Godshall is scheduled to ... 11:00 a.m. MST on Wednesday, November 9, 2011.  The ...
Cached Medicine Technology:St. John Hospital 1st in Region to Offer Innovative Chemotherapy Delivery System 2HeartWare to Present at the Credit Suisse 2011 Healthcare Conference 2
(Date:3/30/2015)... March 30, 2015 Textile Exchange, a ... textile industry, today announced the latest version of its ... certification standard that can be applied to any waterfowl-based ... from hatchling to end product. The goal of the ... animal welfare and to enable traceability so that products ...
(Date:3/30/2015)... On March 11, 2015, Elle Magazine, in ... details six new treatment options for dealing with stubborn, unwanted ... a topical product. The other three technologies use devices to ... or freezing cold ( CoolSculpting ) to kill fat cells. ... to us to permanently remove unwanted fat," says Dr. Simon ...
(Date:3/30/2015)... Vancouver, BC (PRWEB) March 30, 2015 ... ( http://www.idataresearch.com ), the hernia repair market will continue ... market. Growth is occurring primarily due to increasing numbers ... to treat them. , “The significantly large market ... to a generally high ASP. We’re seeing a growing ...
(Date:3/30/2015)... This report studies the global tumor ... to 2019. , Based on the type of ... into four major segments, namely radio-frequency, microwave, cryoablation ... and laser ablation) segments. Moreover, based on type ... classified into three segments, namely, interventional radiology, surgery ...
(Date:3/30/2015)... On March 19th, 2015, in the Hall of Legends ... LiveToBeSober.org hosted the “Fighting Addiction Together” luncheon. Attendees included ... well as other civic leaders and public figures. , ... retired Detroit Lions wide receiver Herman Moore, Live to ... their own personal battles with addiction, Ronald Stevens and ...
Breaking Medicine News(10 mins):Health News:Responsible Down Standard 2.0 Released 2Health News:Responsible Down Standard 2.0 Released 3Health News:UltraShape and CoolSculpting: Two New Fat-Busting Technologies 2Health News:High Prices for Advanced Biologic Hernia Repair Technology Driving European Soft Tissue Reinforcement and Regeneration Market Growth 2Health News:High Prices for Advanced Biologic Hernia Repair Technology Driving European Soft Tissue Reinforcement and Regeneration Market Growth 3Health News:The Global Tumor Ablation Market is Poised to Reach the Value of $462.0 Million in 2019 - MarketsandMarkets Released Recently 2Health News:The Global Tumor Ablation Market is Poised to Reach the Value of $462.0 Million in 2019 - MarketsandMarkets Released Recently 3Health News:LiveToBeSober.org Releases Highlight Reel of Substance Abuse Conference Keynote Speakers 2
... Society (APS) is elated that the Senate has approved ... continue cutting-edge research that will lead to innovation, job ... Specifically, APS lauds the bill,s support of research programs ... National Science Foundation and the National Institute of Standards ...
... North Carolina students interested in earning the doctor of optometry ... by College Foundation of North Carolina and the N.C. State Education ... state:, , ... University (Greenville, NC) - 10:00 a.m. - 12:00 noon, ...
... yesterday, exactly six months after Hurricane Ike slammed the ... the lessons learned from Hurricane Rita. , According to ... they would evacuate if a Category 4 hurricane threatened ... 24 percent of residents who left during the Category ...
... Va., LONDON and GENEVA, March 13 Clinical Care ... and NAM, an award-winning community-based HIV information provider, have ... and news from the 5th International AIDS Society Conference ... Cape Town, South Africa, July 19-22, 2009, and the ...
... March 13 Transcept Pharmaceuticals, Inc. (Nasdaq: ... development and commercialization of proprietary products that address important ... it will report results for its fourth quarter 2008 ... conference call to review the results will begin at ...
... -- China Sky One Medical, Inc.,("China Sky One ... ), a leading fully,integrated pharmaceutical company producing over-the-counter ... announced that Ms. Xiao-yan Han,China Sky One Medical ... Jaffray,& ChinaVenture Conference in Shanghai and The World ...
Cached Medicine News:Health News:Optometry Career Conferences Set for Five N.C. Campuses in March 2Health News:Rice report shows lessons from Hurricane Rita not practiced during Ike 2Health News:Clinical Care Options and NAM Selected by the International AIDS Society to Collaborate on Official Online Conference Coverage From Annual Meetings 2Health News:Clinical Care Options and NAM Selected by the International AIDS Society to Collaborate on Official Online Conference Coverage From Annual Meetings 3Health News:Transcept Pharmaceuticals to Report Fourth Quarter 2008 Results 2Health News:Transcept Pharmaceuticals to Report Fourth Quarter 2008 Results 3Health News:China Sky One Medical to Attend Two Conferences in March 2Health News:China Sky One Medical to Attend Two Conferences in March 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: